3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
6
Not yet recruiting
2
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma, Mantle-Cell
7
Lymphoma, Non-Hodgkin
5
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, B-Cell
3
Leukemia
3
Lymphoma, Follicular
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Lymphoid
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Chromosome 17 deletion
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
21
fludarabine
14
Rituximab
11
Immunotherapy, Adoptive
9
Specimen Handling
8
Vincristine
7
Prednisone
7
Magnetic Resonance Spectroscopy
7
Doxorubicin
7
Etoposide
6
Biopsy
6
glofitamab
5
zanubrutinib
4
polatuzumab vedotin
4
obinutuzumab
4
Lenalidomide
4
Bendamustine Hydrochloride
4
relmacabtagene autoleucel
3
loncastuximab tesirine
3
fludarabine phosphate
3
axicabtagene ciloleucel
3
Leukapheresis
3
Ifosfamide
3
Carboplatin
3
tafasitamab
2
etoposide phosphate
2
X-Rays
2
Nivolumab
2
Injections
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, B-Cell
×
pirtobrutinib
×
Clear all
NCT05254743
2026-04-20
BRUIN-CLL-314
Eli Lilly and Company
Phase 3
Recruiting
662 enrolled